News & Articles
Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs

Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs

Unique phosphatase technology platform offers a new paradigm in oncology. EUR 9M financing, co-led by NVF and Novo Seeds with participation from Advent Life Sciences and a family office, to advance lead compounds to clinical candidate stage.

Read more